03:01 PM EDT, 09/10/2025 (MT Newswires) -- Neurosense Therapeutics ( NRSN ) shares rose more than 39% in recent Wednesday trading after the initial phase 2 trial results of PrimeC to treat Alzheimer's disease showed enhanced neuroplasticity and no treatment-related toxicity.

Neuroplasticity is an important feature in supporting brain health and function. The trial in collaboration with NeuroKaire is designed to assess the safety, efficacy, and biological activity of PrimeC over a year, Neurosense said.

The company said it will present the results at the CNS Summit 2025 in Boston in early November.

NeuroSense and NeuroKaire will continue to assess PrimeC's cellular effects in tandem with clinical outcomes from the phase 2 trial, with top-line data expected after study completion, according to the company.

Price: 1.63, Change: +0.46, Percent Change: +39.32